Oramed Pharmaceuticals (ORMP) Earnings Date, Estimates & Call Transcripts → How’d you do in 2022 (From Brooks Enterprises) (Ad) Free ORMP Stock Alerts $2.16 -0.05 (-2.26%) (As of 06/4/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Earnings SummaryUpcoming Earnings DateAug. 8EstimatedActual EPS (May. 9) $0.04 Beat By $0.02 Consensus EPS (May. 9) $0.02 Get Oramed Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for ORMP and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueORMP Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ORMP Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Brooks EnterprisesHow’d you do in 20222022 was a rough year. At their worst, the S&P 500 was down over 25% and the NASDAQ was down over 35%, and to make things even more interesting the Fed was seemingly raising interest rates every week!Get those kind of results during the Great Financial Crisis, without having to study more Oramed Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241$0.02$0.02$0.02Q2 20242($0.02)$0.04$0.01Q3 20242($0.04)$0.04$0.00Q4 20242($0.09)($0.03)($0.06)FY 20247($0.13)$0.07($0.03)Q1 20251($0.07)($0.07)($0.07)Q2 20251($0.08)($0.08)($0.08)Q3 20251($0.09)($0.09)($0.09)Q4 20251($0.11)($0.11)($0.11)FY 20254($0.35)($0.35)($0.35)ORMP Earnings Date and InformationOramed Pharmaceuticals last issued its earnings data on May 9th, 2024. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. Oramed Pharmaceuticals has generated $0.26 earnings per share over the last year ($0.26 diluted earnings per share) and currently has a price-to-earnings ratio of 8.3. Earnings for Oramed Pharmaceuticals are expected to decrease in the coming year, from ($0.01) to ($0.33) per share. Oramed Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based off prior year's report dates.Read More Oramed Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/8/2024(Estimated)------- 5/9/2024Q1 2024$0.02$0.04+$0.02$0.04--3/6/2024Q4 2023($0.12)($0.08)+$0.04($0.49)--11/9/2023Q3 2023($0.09)($0.08)+$0.01($0.08)--8/10/2023Q2 2023($0.11)($0.03)+$0.08($0.03)$0.70 million$0.67 million5/11/2023Q1 2023($0.23)($0.08)+$0.15($0.08)$0.75 million$0.67 million3/6/2023Q4 2022($0.22)($0.22)-($0.22)$0.75 million$0.68 million Get the Latest News and Ratings for ORMP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/10/2022Q3 2022($0.26)($0.18)+$0.08($0.18)$0.70 million$0.68 million8/10/2022Q2 2022-$0.27+$0.27$0.27-$0.67 million5/12/2022Q1 2022-($0.27)($0.27)($0.27)-$0.67 million1/10/2022Q1($0.1650)($0.22)($0.0550)($0.22)$0.70 million$0.67 million11/24/2021Q4 2021($0.10)($0.21)($0.11)($0.21)$0.80 million$0.68 million7/13/2021Q3($0.20)($0.17)+$0.03($0.17)$0.70 million$0.68 million4/12/2021Q2($0.1750)($0.17)+$0.0050($0.17)-$0.67 million1/13/2021Q1($0.1450)($0.23)($0.0850)($0.23)-$0.67 million11/23/2020Q4($0.2070)($0.12)+$0.0870($0.12)$0.69 million$0.68 million7/7/2020Q3($0.1680)($0.10)+$0.0680($0.10)$0.69 million$0.68 million4/6/2020Q2 2020($0.25)($0.21)+$0.04($0.21)-$0.67 million1/9/2020Q1($0.26)($0.15)+$0.11($0.15)-$0.67 million11/27/2019Q4 2019($0.34)$0.13+$0.47$0.13$0.65 million$0.68 million7/10/2019Q3 2019($0.23)($0.23)-($0.23)$0.71 million$0.68 million Oramed Pharmaceuticals Earnings - Frequently Asked Questions When is Oramed Pharmaceuticals's earnings date? Oramed Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based off last year's report dates. Learn more on ORMP's earnings history. Did Oramed Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Oramed Pharmaceuticals (NASDAQ:ORMP) reported $0.04 earnings per share (EPS) to beat the analysts' consensus estimate of $0.02 by $0.02. Learn more on analysts' earnings estimate vs. ORMP's actual earnings. How much revenue does Oramed Pharmaceuticals generate each year? Oramed Pharmaceuticals (NASDAQ:ORMP) has a recorded annual revenue of $1.34 million. How much profit does Oramed Pharmaceuticals generate each year? Oramed Pharmaceuticals (NASDAQ:ORMP) has a recorded net income of $5.53 million. ORMP has generated $0.26 earnings per share over the last four quarters. What is Oramed Pharmaceuticals's price-to-earnings ratio? Oramed Pharmaceuticals (NASDAQ:ORMP) has a trailing price-to-earnings ratio of 8.31. What is Oramed Pharmaceuticals's EPS forecast for next year? Oramed Pharmaceuticals's earnings are expected to decrease from ($0.01) per share to ($0.33) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Precigen Earnings Neoleukin Therapeutics Earnings Shattuck Labs Earnings Ventyx Biosciences Earnings Nkarta Earnings Xeris Biopharma Earnings Skye Bioscience Earnings UroGen Pharma Earnings Atea Pharmaceuticals Earnings Q32 Bio Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: The Most Upgraded Stocks After the Q1 Earnings Season ZIM Shipping Stock Forecast, Earnings Triggers a BuyHormel: A Potential Buy Despite Post-Earnings DeclineCanopy Growth’s Earnings: Profitability Despite Industry ShiftsAbercrombie & Fitch First Quarter Earnings Surge to New HeightsTD Bank Q2 Earnings: Record Highs and Regulatory HurdlesPDD Holdings Earnings Volatility Alerts Buyers This page (NASDAQ:ORMP) was last updated on 6/4/2024 by MarketBeat.com Staff From Our PartnersWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises| SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals| SponsoredForget the Kitty! 7 stocks better than GME or AMCIn 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club| Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC| SponsoredWhat’s Pelosi Buying Now?They Make the Top Investors Look Like Amateurs They beat the market for three years straight… avoided some ...Altimetry| SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media| SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings| SponsoredClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an eff...Crypto Swap Profits| Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.